Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma

Blog Article

Adam Yuh Lin,1 Joseph Michael Schnitter,2 Leo I Gordon1 1Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; 2Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USACorrespondence: Adam Yuh Lin, Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Arkes Pavilion, 676 N St Clair Street Suite 850, Chicago, IL, 60611, USA, Email adam.lin@northwestern.eduAbstract: Classical Hodgkin lymphoma is biologically different than other lymphomas.

The cancer cells nova upright walker only occupy a small amount of the lymph node and evade the immune system by amplification of PD-L1 and PD-L2.Therefore, checkpoint inhibitors are a logical treatment option for Hodgkin lymphoma patients to unlock the immune system.Checkpoint inhibitors have shown high response rates in clinical trials in advanced-stage Hodgkin lymphoma.

The two most commonly used checkpoint inhibitors are pembrolizumab and nivolumab, both FDA approved as third-line cirque colors lavender sky therapy.There is increasing interest in the use of checkpoint inhibitors with combination chemotherapy or with other targeted agents in the second-line or even frontline setting.In this review, we will highlight the clinical trials that led to approvals of checkpoint inhibitors for Hodgkin lymphoma.

Keywords: checkpoint inhibitor, pembrolizumab, nivolumab, Hodgkin lymphoma.